SPECT imaging of inflammatory response in ischemic-reperfused rat hearts using a 99mTc-labeled dual-domain cytokine ligand

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2139-2145

  Liu, Zhonglin ^a   Barber, Christy ^a   Wan, Li ^a   Liu, Shan ^b   Hui, Mizhou M ^b,c   Furenlid, Lars R ^a   Xu, Hua ^a   Woolfenden, James M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b INSTITUTE OF PROCESS ENGINEERING   (China)

^c AmProtein Corporation   (United States)

Author keywords

Inflammation; Interleukin 1; Myocardial ischemia reperfusion; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM FC INTERLEUKIN 1 RECEPTOR ANTAGONIST TC 99M CYTOKINE RADIOLIGAND; TECHNETIUM TUMOR NECROSIS FACTOR RECEPTOR 2 FC INTERLEUKIN 1 RECEPTOR ANTAGONIST TC 99M DUAL DOMAIN CYTOKINE LIGAND; TECHNETIUM TUMOR NECROSIS FACTOR RECEPTOR 2 FC TC 99M CYTOKINE RADIOLIGAND; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; HYBRID PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIGAND; TECHNETIUM COMPLEX; TUMOR NECROSIS FACTOR RECEPTOR 2; DIAGNOSTIC AGENT; INTERLEUKIN 1; TECHNETIUM 99M; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARDIAC IMAGING; CARDITIS; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG UPTAKE; EX VIVO STUDY; HEART MUSCLE BLOOD FLOW; IMAGE PROCESSING; IMAGE RECONSTRUCTION; IMMUNOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MALE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; RAT; REPERFUSION INJURY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; THREE DIMENSIONAL IMAGING; UPREGULATION; ANIMAL; DIAGNOSTIC USE; GENE EXPRESSION REGULATION; HEART; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; SCINTISCANNING; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL; MYOCARDIAL ISCHEMIA-REPERFUSION;

ANIMALS; BIOLOGICAL TRANSPORT; CORONARY CIRCULATION; CYTOKINES; GENE EXPRESSION REGULATION; HEART; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; ISOTOPE LABELING; LIGANDS; MALE; ORGANOTECHNETIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; REPERFUSION INJURY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR NECROSIS FACTOR-ALPHA;

99MTC; INFLAMMATION; INTERLEUKIN-1; MYOCARDIAL ISCHEMIA-REPERFUSION; TUMOR NECROSIS FACTOR;

EID: 84893358563     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.123497     Document Type: Article

References (40)

1. Blancke F, Claeys MJ, Jorens P, et al. Systemic inflammation and reperfusion injury in patients with acute myocardial infarction. Mediators Inflamm. 2005;2005:385-389.
2. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem. 2006;13:1877-1893.
3. Jefferson BK, Topol EJ. Molecular mechanisms of myocardial infarction. Curr Probl Cardiol. 2005;30:333-374.
4. Ren G, Dewald O, Frangogiannis NG. Inflammatory mechanisms in myocardial infarction. Curr Drug Targets Inflamm Allergy. 2003;2:242-256.
5. Zhao ZQ, Velez DA, Wang NP, et al. Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis. 2001;6: 279-290.
6. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-1553.
7. Pudil R, Pidrman V, Krejsek J, et al. Cytokines and adhesion molecules in the course of acute myocardial infarction. Clin Chim Acta. 1999;280:127-134.
8. Deten A, Volz HC, Briest W, Zimmer HG. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res. 2002;55:329-340.
9. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol. 1995;146:419-428.
10. Dunne A. Inflammasome activation: from inflammatory disease to infection. Biochem Soc Trans. 2011;39:669-673.
11. Mills KH, Dunne A. Immune modulation: IL-1, master mediator or initiator of inflammation. Nat Med. 2009;15:1363-1364.
12. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 1990;343:341-346.
13. Bresnihan B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. BioDrugs. 2001;15:87-97.
14. Efthimiou P, Markenson JA. Role of biological agents in immune-mediated inflammatory diseases. South Med J. 2005;98:192-204.
15. Frangogiannis NG, Lindsey ML, Michael LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. 1998;98: 699-710.
16. Reil JC, Gilles S, Zahler S, et al. Insights from knock-out models concerning postischemic release of TNFa from isolated mouse hearts. J Mol Cell Cardiol. 2007;42:133-141.
17. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA. 1992;89:4845-4849.
18. Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med. 1999;27:1309-1318.
19. Woldbaek PR, Tonnessen T, Henriksen UL, et al. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc Res. 2003;59:122-131.
20. Kan H, Xie Z, Finkel MS. TNF-alpha enhances cardiac myocyte NO production through MAP kinase-mediated NF-kappaB activation. Am J Physiol. 1999;277: H1641-H1646.
21. Gurantz D, Cowling RT, Varki N, Frikovsky E, Moore CD, Greenberg BH. IL- 1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol. 2005;38:505-515.
22. Liu Z, Wyffels L, Barber C, et al. Characterization of 99mTc-labeled cytokine ligands for inflammation imaging via TNF and IL-1 pathways. Nucl Med Biol. 2012;39:905-915.
23. Xie B, Liu S, Wu S, et al. A novel bifunctional protein TNFR2-Fc-IL-1ra (TFI): expression, purification and its neutralization activity of inflammatory factors. Mol Biotechnol. 2013;54:141-147.
24. Tesic M, Sheldon KM, Ballinger JR, Boxen I. Labelling small quantities of monoclonal antibodies and their F(ab')2 fragments with technetium-99m. Nucl Med Biol. 1995;22:451-457.
25. Mishra AK, Iznaga-Escobar N, Figueredo R, et al. Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITCDTPA immunoconjugates of anti-EGF-receptor antibodies. Methods Find Exp Clin Pharmacol. 2002;24:653-660.
26. Min JY, Chen Y, Malek S, et al. Stem cell therapy in the aging hearts of Fisher 344 rats: synergistic effects on myogenesis and angiogenesis. J Thorac Cardiovasc Surg. 2005;130:547-553.
27. Nikolaidis LA, Doverspike A, Huerbin R, Hentosz T, Shannon RP. Angiotensinconverting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation. 2002;105:2785-2790.
28. Guide for the Care and Use of Laboratory Animals. Bethesda, MD: National Institutes of Health, 1985. NIH publication 85-23.
29. van Eerd JE, Oyen WJ, Harris TD, et al. Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytes. J Nucl Med. 2005;46:786-793.
30. van Eerd JE, Broekema M, Harris TD, et al. Imaging of infection and inflammation with an improved 99mTc-labeled LTB4 antagonist. J Nucl Med. 2005;46:1546-1551.
31. Lee WW, Marinelli B, van der Laan AM, et al. PET/MRI of inflammation in myocardial infarction. J Am Coll Cardiol. 2012;59:153-163.
32. Cawthorne C, Prenant C, Smigova A, et al. Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [18F]- IL1RA and PET imaging in rats. Br J Pharmacol. 2011;162:659-672.
33. van der Laken CJ, Boerman OC, Oyen WJ, van de Ven MT, van der Meer JW, Corstens FH. Imaging of infection in rabbits with radioiodinated interleukin-1 (alpha and beta), its receptor antagonist and a chemotactic peptide: a comparative study. Eur J Nucl Med. 1998;25:347-352.
34. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation. 1998;98:149-156.
35. Yue P, Massie BM, Simpson PC, Long CS. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol. 1998;275: H250-H258.
36. Grünenfelder J, Miniati DN, Murata S, et al. Upregulation of Bcl-2 through caspase-3 inhibition ameliorates ischemia/reperfusion injury in rat cardiac allografts. Circulation. 2001;104:I202-I206.
37. Berthonneche C, Sulpice T, Boucher F, et al. New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am J Physiol Heart Circ Physiol. 2004;287:H340-H350.
38. Toufektsian MC, Robbez-Masson V, Sanou D, et al. A single intravenous sTNFR-Fc administration at the time of reperfusion limits infarct size-implications in reperfusion strategies in man. Cardiovasc Drugs Ther. 2008;22:437-442.
39. Wallach D, Engelmann H, Nophar Y, et al. Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl. 1991;35:51-57.
40. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988;53:45-53.